BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

DualityBio, BioNTech Expand Partnership for Solid Tumor Antibody-Drug Conjugate

The agreement further builds upon the strategic collaboration the companies announced in April 2023. Under the terms of the agreements, DualityBio will re...

August 08, 2023 | News

Peter Mac launches BindiMaps to help patients and visitors with vision impairments

The newly-installed service functions like Google Maps, but has been specifically developed to work indoors with a 10 to 20 times higher accuracy than GPS ...

August 03, 2023 | News

AI Medical Service Inc. Signs Joint Research Agreement with Stanford Medicine

AI Medical Service Inc. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research...

July 28, 2023 | News

GC Genome Enables Prognosis Prediction and Targeted Treatment in Breast Cancer

''We can gain vital insights into patient prognosis and make informed decisions regarding the most effective treatment strategies through ctDNA CNA...

July 27, 2023 | News

HaemaLogiX, Peter MacCallum Cancer Centre Announce Myeloma CAR-T Trial Agreement

HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's ...

July 26, 2023 | News

Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial

SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) is a Phase II Positron Emission Tomography (PET) imaging tr...

July 25, 2023 | News

BGI Genomics Global Cervical Cancer Survey Finds Young Women Have Higher Vaccination Rates but 43.5 percent Put off by Pap Smears

To further inform action to combat cervical cancer, the fourth most common cancer among women globally, BGI Genomics released its State of Cervi...

July 24, 2023 | News

Doer Biologics Announces License Agreement with BioNTech

Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide license to utilize one of Doer Bio's innovative discoveries to research, develop...

July 12, 2023 | News

NK:IO Secures £1.6M Innovate UK Grant for Pioneering Cancer Therapy

Grant award of £1.6M supports program of development work with Cell and Gene Therapy Catapult NK:IO’s platform, based on pionee...

July 11, 2023 | News

3D bioprinting technology to be used for removing cancer cells

□ A three-dimensional (3D) bioprinting technology capable of eliminating cancer cells using the function of immune cells has been developed for t...

July 11, 2023 | News

280 Bio receives IND approval from the FDA for YL-17231

80Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the U.S. Food and Drug ...

July 10, 2023 | News

Hexvix® Completes Phase III Bridging Trial Enrollment for Bladder Cancer

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

July 10, 2023 | News

GeneQuantum Healthcare and Aimed Bio collaborate to develop 5 innovative ADC drugs

Since April of last year, GeneQuantum and Aimed Bio have been collaborating on the joint development of a FGFR3-targeting ADC named GQ1011/AMB302. The prog...

July 07, 2023 | News

I-Mab Publishes Givastomig, a Claudin18.2 x 4-1BB Bispecific Antibody, in JITC

Givastomig is engineered to bind to CLDN18.2-expressing cancer cells and co-stimulatory receptor 4-1BB on adjacent T cells, with the aim of activating...

July 06, 2023 | News

Stay Connected